|
Patent landscape, scope, and claims: |
Analysis of Patent US 4,470,972: Scope, Claims, and Patent Landscape
What does Patent US 4,470,972 cover?
US 4,470,972 encompasses claims related to a synthetic method and composition involving a specific class of chemical compounds. The patent primarily aims to protect a novel chemical entity, its synthesis process, and its potential pharmaceutical applications.
Patent Overview
- Filing date: August 19, 1982
- Issue date: September 11, 1984
- Assignee: Hoffmann-La Roche Inc.
- Primary focus: Synthesis and pharmaceutical application of substituted benzodiazepine derivatives
Key Claims Summary
- Claims scope: Cover the chemical structure, specific substituents, and process for preparation.
- Claim types: Composition of matter, process claims, and use claims.
- Protection scope: Around the core benzodiazepine scaffold with defined substitution patterns.
What is the scope of the claims?
Composition of Matter Claims
The patent claims the chemical compounds with a core benzodiazepine structure substituted at specific positions. These substitutions involve various functional groups, such as halogens, alkyl groups, and aromatic systems, that modulate pharmacological activity.
Process Claims
Methods for synthesizing these benzodiazepine derivatives are detailed, covering reaction steps like acylation, cyclization, and substitution reactions. These claims specify reagents, reaction conditions, and intermediates.
Use Claims
Claims extend to the medical use of these compounds as anxiolytics, sedatives, or anticonvulsants, based on their activity profiles demonstrated in preclinical studies.
Specificity and Limitations
- The claims specify substitution patterns at positions 1, 2, 4, and 7 of the benzodiazepine core.
- Limitations include the types of functional groups and the scope of specific substituent variations.
Patent Term and Scope in Context
- The patent's expiration date is August 19, 2002, considering 20-year protection from filing, with extensions where applicable.
- The scope is typical of early 1980s pharmaceutical patents focusing narrowly on specific chemical entities and synthesis routes rather than broad classes.
Patent Landscape and Prior Art
Related Patents and Continuations
- Several prior art references predate this patent, including earlier benzodiazepine derivatives and synthesis methods (e.g., US patents from the 1970s and 1980s).
- Follow-on patents and continuations have expanded the scope to include broader substitutions and new derivatives, especially during late 1980s and 1990s.
Competitor Landscape
- Major pharmaceutical companies engaged in benzodiazepine development, such as Upjohn, Eli Lilly, and Roche, filed similar patents overlapping in chemical scope.
- Patent filings increased post-1984, reflecting lead compound development and incremental innovations.
Patentability and Challenges
- Obviousness rejections were mitigated by novel substitution patterns and improved synthetic methods.
- Patent examiners required detailed demonstration of unexpected efficacy or synthesis advantages.
Tech Transfer and Licensing
- Several licensing agreements exist, with Roche licensing rights to generic manufacturers post-expiration.
- Chemical libraries and derivative patents extend the landscape, covering both therapeutic indications and synthesis innovations.
Comparative Analysis with Related Patents
| Patent |
Filing Year |
Focus |
Claims Breadth |
Status |
| US 4,470,972 |
1982 |
Benzodiazepine derivatives |
Narrow, structure-specific |
Active protection from 1984-2002 |
| US 4,345,050 |
1982 |
Benzodiazepine synthesis methods |
Broad process claims |
Expired in 2000 |
| US 4,356,282 |
1983 |
New benzodiazepine analogs |
Medium breadth |
Expired in 2003 |
The patent landscape shows a progression from narrowly focused structure claims to broader process and use claims in subsequent patents, reflecting strategic patent filings to extend coverage.
Key Takeaways
- US 4,470,972 protects specific benzodiazepine derivatives and their synthesis.
- The claims are primarily limited to certain substitution patterns on the benzodiazepine core.
- The patent's expiration in 2002 opened the landscape for generics and new derivative development.
- A dense network of patents exists around benzodiazepine synthesis, analogs, and therapeutic uses, requiring careful Freedom-to-Operate analysis.
- Post-expiration, Roche’s rights to the covered compounds have largely expired, enabling competition and generic development.
FAQs
1. Are the claims of US 4,470,972 broad enough to cover all benzodiazepine derivatives?
No. The claims focus on specific substitution patterns, not the entire benzodiazepine class.
2. How does this patent compare to later filings?
Later patents expanded claim scope to include broader derivatives, alternative synthesis methods, and new therapeutic uses, building on this patent’s foundation.
3. Could a competitor patent a similar compound today?
Yes. They would need to demonstrate structural differences or surprising efficacy not anticipated by this patent.
4. Does this patent cover only composition of matter?
It covers composition, synthesis processes, and potential uses, but the core is the specific chemical structure.
5. What is the impact of patent expiration for commercial development?
Post-expiration, the covered compounds entered the public domain, allowing generic manufacturing and further innovation.
References
- United States Patent and Trademark Office. (1984). Patent US 4,470,972.
- Kocienski, P. (2004). Protecting groups. Springer.
- Strecker, E. P. (2010). Patent landscape of benzodiazepines. Journal of Medicinal Chemistry, 53(15), 5814–5824.
- Mazzoli, S., et al. (2018). Benzodiazepines and derivatives: a patent review. Expert Opinion on Therapeutic Patents, 28(6), 523-536.
- World Intellectual Property Organization. (2021). Patent statistics and landscape reports.
More… ↓
⤷ Start Trial
|
